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Abstract In the presented work, amphiphilic nanopar-
ticles based on chitosan and carboxy-enriched polylactic
acid have been prepared to improve the stability of the
pro-drug temozolomide in physiological media by en-
capsulation. The carrier, with a diameter in the range of
150–180 nm, was able to accommodate up to 800 μg of
temozolomide per mg of polymer. The obtained formu-
lation showed good stability in physiological condition
and preparation media up to 1 month. Temozolomide
loaded inside the carrier exhibited greater stability than
the free drug, in particular in simulated physiological
solution at pH 7.4 where the hydrolysis in the inactive
metabolite was clearly delayed. CS-SPLA nanoparticles
demonstrated a pH-dependent TMZ release kinetics
with the opportunity to increase or decrease the rate.
Mass spectroscopy, UV-Vis analysis, and in vitro cell
tests confirmed the improvement in temozolomide sta-
bility and effectiveness when loaded into the polymeric
carrier, in comparison with the free drug.
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Abbreviations
1H–NMR Proton nuclear magnetic resonance
AIC 5-Aminoimidazole-4-carboxamide
CS Chitosan
CS-SPLA Chitosan grafted carboxy enriched
polylactic acid
D Molar mass dispersity
DLS Dynamic light scattering
DNA Deoxyribonucleic acid
DR Drug released
DS Dextran sulfate
EDC 1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide
EE Encapsulation efficiency
FTIR-ATR Fourier transform infrared-attenuated
total reflection
GBM Glioblastoma multiforme
GPC Gel permeation chromatograpy
LC-MS Liquid chromatograpy-mass spectrometry
MEF Mouse embryonic fibroblasts
Mn Molar mass distribution
MTIC 5-(3-Methyl-triazen-1-yl) imidazole-
4-carboxamide
Mw Weight-average molecular weight
NHS N-Hydroxysuccinimide
NIH/3 T3 3-Day transfer standard fibroblast
PA Pentetic acid
PBCA Polybutyl cyanoacrylate
PBS Phosphate buffer solution
PCS Photon correlation spectroscopy
PLGA Polylactic-co-glycolic acid
S Swelling
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Introduction
Temo z o l om i d e ( TMZ ) ( 8 - c a r b am o y l - 3 -
methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one) be-
longs to the class of alkylating agents known as
imidazotetrazines and represents one of the major che-
motherapeutic agents used in glioblastoma multiforme
(GBM) treatment (Appel et al. 2012; Dresemann 2010;
Hegi et al. 2005). It is a prodrug, which crosses the
blood–brain barrier, and is converted via hydrolysis
under physiological conditions in the active form 5-(3-
methyl-triazen-1-yl) imidazole-4-carboxamide (MTIC).
TMZ degradations in the MTIC occur after uptake by
GBM cells in the brain. The MTIC methylates DNA in
the O6 position of guanine residues, causing cytotoxic
DNA damage (Meer et al. 1986).
TMZ hydrolysis can also take place in the blood
stream. Nevertheless, the MTIC is not able to cross the
blood–brain barrier and exhibits low cell absorption,
thereby diminishing therapeutic efficiency.
According to the literature (Appel et al. 2012;
Lagona et al. 2005), improving the half-life of
TMZ under physiological conditions would promote
greater accumulation of the TMZ accessing the
GBM site, prior to degradation. Consequently, the
drug would be more effective, and lower doses
could be utilized to maintain the current therapeutic
window.
Different approaches have been reported, ranging
from chemical modification to coating procedures, al-
though recent years havewitnessed considerable interest
in techniques for TMZ encapsulation into polymeric
microparticles and nanoparticles.
Nanoparticles, thanks to their unique properties, are
under active study as drug delivery carriers for the
treatment of disease (Koo et al. 2006; Fahr and Liu
2007). Polymeric-based nanoparticles have become tre-
mendously important in developing such systems due to
their tunable characteristics and potential to entrap, dis-
solve, or attack a wide range of drugs or other active
pharmaceutical ingredients (APIs) (McCarron and Hall
2004; Lu et al. 2006; Wen and Kesari 2008; Jeyarama
et al. 2016; Agarwala and Kirkwood 2000a, b).
Particular interest has been shown in biopolymers,
especially polysaccharides, due to peculiarities such as a
large number of reactive groups, a wide range of mo-
lecular weights (MW), and variation in chemical com-
position according to the source (Sinha and Kumria
2001), these properties allowing for preparation of a
carrier with well-defined properties.
Chitosan belongs to the group of polysaccharides and
can easily be prepared through partial or total
deacetylation of chitin. It is a copolymer of D-glucos-
amine and N-acetyl-D-glucosamine, linked by β-(1,4)
glycosidic bonds. It has been widely applied in the
pharmaceutical and medical sectors as a consequence
of the favorable biological properties pertaining to it,
such as biodegradability (Bowman and Leong 2006).
Chemically modifying CS, in particular through grafting
procedures, appears promising for developing highly
tailored drug carriers for controlled and sustained deliv-
ery of selected APIs. As reported in our paper and other
published works, modification of CS by introduction of
polylactic acid chains presented several advantages
(Wang et al. 2014a, b; Ge et al. 2015; Huang et al.
2013; Di Martino and Sedlarik 2014).
Several works have been published regarding the
encapsulation of TMZ in nanocarrier of various natures.
However, the main concern was to improve the selec-
tivity of the drug, avoid the development of resistance
mechanism from the cancer cells, and reduce side effects
related to the administration frequency (Jain et al. 2014;
Xu et al. 2015). Only a few works, dealing with the use
of nanoparticles, in particular those based on polymers,
improving TMZ stability in physiological conditions by
delaying the hydrolysis process, are reported.
Most of the studies focused on the increment of stabil-
ity deal with the chemical modification of TMZ. It repre-
sents a valid strategy, which already demonstrated good
results, as a lot has been published about imidazotetrazines
chemistry (Matosiuk et al. 2002; El-Sharief et al. 2006;
Tyndall et al. 2015). However, the chemical modification
is a longer and more complicated procedure than encap-
sulation in specific nano-sized carrier, which is—in some
cases—fast, highly reproducible, and solvent free.
The presented work is focused on the preparation
of amphiphilic nanoparticles based on CS grafted by
carboxy-enriched polylactic acid (SPLA), with the
aim of loading and improving the stability of TMZ
in simulated physiological conditions, in particular
at pH >7. Nanoparticles based on CS-grafted SPLA
(CS-SPLA) were characterized in terms of
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dimension, surface properties, and stability in differ-
ent media. The capacity of the prepared nanoparti-
cles to load, release for an extended period, and
improve TMZ stability by delaying hydrolysis, in
particular at pH >7, were demonstrated by UV–Vis
spectrophotometry and LC-MS analysis. Cytotoxic-
ity tests on two mouse fibroblast cell lines (MEF
and NHT/3T3) demonstrated the safety of the bare
CS-SPLA nanoparticles and their capability to en-
hance TMZ stability and efficacy, compared to the
free drug.
Materials and methods
Materials
Chitosan (20–300 cP, 1 wt.% in 1% acetic acid
(25 °C, Brookfield), D.D 75–85%), dextran sulfate
(Mw 40 kDa), dimethyl sulfoxide in deuterated form
(DMSO-d6), pentetic acid (PA) (N,N-Bis(2-
bis(carboxymethyl)amino]ethyl)glycine, ≥99.5% ),
methanesulfonic acid (MSA, ≥95%), hydrochloric
acid (HCl, 30% for trace analysis), doxorubicin hy-
drochloride, and 5-fluorouracil were supplied by
Sigma Aldrich. L-Lactic acid (80% water solution)
was purchased from Merci s.r.o., Czech Republic.
Sodium hydroxide, sodium phosphate, potassium
phosphate, and potassium hydroxide were bought
from IPL Lukes, Uhresky Brod, Czech Republic.
Acetic acid CH3CO2H (HPLC grade) was purchased
from Chromspec, Brno, Czech Republic. The sol-
vents acetone and methanol, the indicator phenol-
phthalein, and potassium hydroxide (all analytical
grade) were bought from IPL Lukes, Uhersky Brod,
Czech Republic. Tetrahydrofuran (HPLC grade) was
purchased from Chromservis, Czech Republic.
Methods
Synthesis and characterization of SPLA and CS-SPLA
conjugate
SPLA was synthetized and characterized following a
procedure reported elsewhere (Kucharczyk et al.
2016). In brief, 1 g of pentetic acid (PA) was mixed
with lactic acid water solution and heated at 110 °C for
1 h under reflux. Then, 0.5 wt.% of methanesulfonic
acid was added and the temperature raised to 130 °C.
Afterward, pressure was decreased in two stages to
<1 kPa. The resulting product was allowed to cool down
at room temperature, after which it was dissolved in
acetone. The polymer solution was precipitated into a
mixture of chilled methanol and distilled water 1:10 (v/
v), then filtrated, washed with water and methanol, and
dried at 30 °C for 48 h in a vacuum oven (10 kPa).
The concentration of –COOH groups in SPLA was
determined by titration in dichloromethane with 0.01 M
KOH ethanol solution using phenolphthalein as an in-
dicator. The concentration of –COOH was obtained
according to the following equation:
CCOOH ¼ a−bð Þ*Nm
 
ð1Þ
where a and b are the volumes (mL) for titration of the
sample and blank, respectively;N the normality of KOH
(mol/L); and m the sample weight (g).
The molecular weight of the SPLA obtained was
characterized by GPC (Agilent HT-GPC 220)
equipped with a dual detection system (refractive
index and viscometric detector), PL gel-mixed bed
columns (1× Mixed-B, 300 × 7.8 mm, 10 μm parti-
cles +1× Mixed-D, 300 × 7.8 mm, 5 μm particles
+1× Mixed-E, 300 × 7.8 mm, 3 μm particles) at
40 °C in THF. The flow rate was set at 1.0 mL min−1
and the injection volume at 100 μL. The GPC sys-
tem was calibrated with narrow polystyrene stan-
dards ranging from 162 to 72,000 g mol−1 (Polymer
Laboratories Ltd., UK). The weight average molar
mass Mw, number average molar mass Mn, and
molar-mass dispersity (Đ = Mw/Mn) were deter-
mined from the peak corresponding to the polymer.
The amphiphi l ic polymer CS-SPLA was
synthetized in accordance with a procedure reported
previously (Di Martino and Sedlarik 2014), based on
a coupling reaction between CS amino groups and
PLA carboxylic groups. CS (0.5 g) was dissolved in
an aqueous solution of 1% v/v acetic acid at 1 mg/
mL concentration, while 0.5 g of SPLA, EDC, and
N-hydroxysuccinimide (NHS) (at the molar ratio
SPLA/EDC/NHS = 1:1.5:3) was dissolved in
50 mL of chloroform. Afterward, the solution con-
taining SPLA was added to CS and kept under
vigorous stirring for 48 h at room temperature. The
reaction was stopped and the final product was
precipi tated by adding NaOH 0.1 M, then
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centrifuged for 15 min at 14,000 rpm, accurately
washed with water and freeze-dried.
The physicochemical structure of the prepared poly-
mer (SPLA) was analyzed by 1H-NMR (Varian Unity
Inova at 400 MHz). The occurrence of the coupling
reaction was confirmed by Fourier Transform infrared
spectroscopy–attenuated total reflectance (FTIR-ATR)
analysis (on a Nicolet iS5 FTIR Spectrometer equipped
with an iD5 ATR accessory and ZnSe crystal, at resolu-
tion 4 cm−1, with 64 scans).
Preparation and characterization of CS-SPLA
nanoparticles loaded with TMZ
The nanoparticles were obtained by dissolving CS-
SPLA (2 mg/mL) in acetic acid solution (pH 5.5)
and DS in distilled water (0.5 mg/mL). A water
solution containing TMZ (0.5 mg/mL) was pre-
pared, added to the DS solution, and kept under
stirring for 30 min. In order to avoid TMZ hydro-
lysis, the solution was acidified to pH 6 by acetic
acid. Afterward, the solution containing DS and
TMZ was added dropwise to the CS-SPLA solution
and kept under vigorous stirring for 1 h at 40 °C.
The pH of the solution was maintained at pH 5.5
for the entire process.
An aliquot of the solution containing the nano-
particles was withdrawn and filtered (0.45 μm) to
remove the presence of dust and aggregates and
analyzed by photon correlation spectroscopy
(PCS), so as to determine the average diameter of
the nanoparticles, as well as by ζ-potential (Nano
ZS Malvern Instruments, UK). The remainder was
centrifuged at 14,000 rpm for 15 min, and the pellet
recovered and freeze-dried.
The shape of the TMZ loaded and unloaded
freeze-dried CS-SPLA nanoparticles was investigat-
ed by scanning electron microscopy (PHENOM
desk top SEM).
The stability of the nanoparticles in solution con-
stitutes an important feature for evaluation. The
change in dimension and ζ-potential of bare nano-
particles over time was investigated by PCS in two
different environments—preparation media (pH 5.5)
and phosphate buffer (pH 7.4) at room temperature.
TMZ encapsulation efficiency (EE) in the CS-SPLA
nanoparticles was determined by UV–Vis spectropho-
tometry (Cary 300 Varian) at 327 nm. The concentration
of the drugs was obtained from the calibration curve of
the free drug in solution. EE values were obtained by the
following equation:
EE %ð Þ ¼ Dt−Df
Dt
 
 100 ð2Þ
where Dt represents the total amount of drug loaded
(mg) and Df the amount of free drug detected in the
supernatant (mg).
The swelling behavior of the obtained material was
determined following the reported procedure (Bajpai
and Anjali 2003).
Nanoparticles (0.5 g) were allowed to swell in a
defined volume (50 mL) of media and taken out
afterward; then, the superficial water was removed
and weighed. The weight of the swollen nanoparti-
cles was monitored at intervals of 2 min till no gain
in weight was recorded, indicating that equilibrium
had been reached.
The following equation was used to determine the
percentage of swelling (S):
S ¼ Ws−Wd
Wd
 100 ð3Þ
where Ws is the weight (mg) of the nanoparticles in the
state of swelling, whileWd is weight (mg) in lyophilized
form (powder) (Bajpai et al. 2012).
TMZ release and stability studies
In vitro release studies were carried out in phosphate
buffer solution (PBS pH 7.4) and simulated gastric fluid
(SGF pH 2) at 37 °C.
In brief, 50 mg of loaded nanoparticles were
suspended in 50 mL of media, following which they
were kept at 37 °C and orbitally shaken at 120 rpm (on
a Stuart Orbital GFL 3033 Shaking Incubator). At
predetermined time intervals, an aliquot (3 mL) was
withdrawn and analyzed on a UV–Vis spectrophotome-
ter. The dissolution medium was replaced with a fresh
one to maintain total volume. The amount of drug re-
leased (DR) was determined by the following equation:
DR %ð Þ ¼ Dt
D0
 
 100 ð4Þ
where Dt (mg) represents the amount of drug released at
time t, and D0 (mg) is the amount of drug loaded. All
studies were conducted in triplicate.
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Concentration (C) data were evaluated by applying a
zero-order (Eq. 5) and first-order equation (Eq. 6) with
GraphPad Prism software (Version 6.04, San Diego,
CA, USA):
Qt ¼ Q0 þ kt ð5Þ
where Q0 represents the initial amount of drug (mg), Qt
the cumulative amount of drug (mg) released at time t
(h), and k (h−1) the release constant;
C ¼ Cmax  1−ekt
  ð6Þ
C is the cumulative concentration (mg drug/mg poly-
mer) of the drug released at given time t (h), Cmax
represents the maximum value of concentration that
can be released from the tested system under the given
conditions (mg drug/mg polymer), and k is the kinetic
constant (h−1) that represents the intensity of release
from the particles at the initial time (t).
In order to prove that no alteration in TMZ structure
occurred after encapsulation and release, analysis in the
form of LC-MS (6530 Accurate-Mass Q-TOF LC/MS
Agilent Technologies, ion mode positive, ionization
ESI, collision energy 10 eV) was carried out on solu-
tions presenting TMZ release after 6 and 24 h.
TMZ (10 μg/mL) dissolved as the free drug in the
tested media was used as the control. Chromatographic
separation was achieved using a column (ZORBAX
Extended-C18, 2.1 × 50 mm, 1.8-Micron, 600 Bar,
Agilent) and mobile phase with 60% water (containing
0.1% of formic acid) and 40% methanol at the flow rate
of 0.3 mL/min. The sample compartment was main-
tained at 37 °C, while the column stood at
30 °C ± 1 °C, and the wavelength was monitored at
325 nm; injection volume equaled 2 μL.
Cytotoxicity and cell morphology
Cytotoxicity testing was performed using a mouse em-
bryonic fibroblast continuous (ATCC CRL-1658™
NIH/3T3) cell line. The culture medium comprised
ATCC–formulated Dulbecco’s modified Eagle’s medi-
um (BioSera, France), containing 10% calf serum
(BioSera, France) and penicillin/streptomycin at
100 U mL−1 (PAA Laboratories GmbH, Austria).
The tested samples were diluted to concentrations of
5 μg mL−1 in the culture medium. Cytotoxicity testing
was conducted according to the EN ISO 10993-5 stan-
dard, withmodification. Cells were precultivated for 24 h,
and the culture medium was subsequently replaced with
dilutions of samples. As a reference, cultivation in pure
medium without the presence of samples was used. In
order to assess cytotoxic effect, anMTTassay (Invitrogen
Corporation, USA) was performed after 24, 48, and 72 h
of cell cultivation with the presence of samples. All the
tests were performed in quadruplicate. Absorbance was
measured at 570 nm by an Infinite M200 Pro NanoQuant
absorbance reader (Tecan, Switzerland). Dixon’s Q test
was applied to remove outlying values and mean values
were calculated. Cell viability is shown as the percentage
of cells present in each respective extract relative to the
cells cultivated in pure extraction medium without colloi-
dal polyaniline (100% viability).
Cells were precultivated for 24 h, and the culture
medium was subsequently replaced with dilutions of
samples. After 24 h of exposure, staining with Hoechst
33258 (Invitrogen, USA) and ActinRed™ 555 (Thermo
Fisher Scientific, USA) was utilized to determine cell
morphology. Prior to this the cells had been fixed and
permeabilized. The cells were fixed using 4% formal-
dehyde (Penta, Czech Republic) for 15 min, washed by
PBS, and subsequently poured with 0.5% Triton X-100
(Sigma-Aldrich, USA) for 5 min to facilitate perme-
abilization. Following this, the cells were washed three
times by PBS (Invitrogen, USA). The required amount
of PBS—two drops per 1 mL of ActinRed™ 555 and
5 μg mL−1 of Hoechst 33258—was added and left to
incubate for 30 min in the dark. The changes in cell
morphology were observed on an Olympus inverted
fluorescent microscope (Olympus, IX 81).
Statistical analysis
Data obtained via the DLS and UV–Vis experiments
underwent one-way analysis of variance (ANOVA) with
a Tukey’s post hoc multiple comparison test using
GraphPad Prism software (Version 6.04, San Diego,
CA, USA). Probability values (p) of less than 0.05 were
considered statistically significant.
Results and discussions
SPLA and CS-SPLA conjugate characterization
According to the GPC data, SPLA exhibits slightly
higher Mn (3.8 kg/mol) and Mw (5.5 kg/mol) values
than the reference linear PLA, which showed 2.4
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and 4.1 kg/mol, respectively. This indicates that
several lactic acid monomers were attached to the
PA carboxylic groups, producing fractions with
higher molecular weights.
Proof of the branched structure of SPLA stems from
intrinsic viscosity values (IVs). In fact, SPLA possesses
an IV of 0.045 dL/g, which is lower than linear PLA
(0.07 dL/g), despite presenting a higher molecular
weight (Kucharczyk et al. 2016).
The most significant information derived from 1H-
NMR spectroscopy relates to the COOH/OH ratio, in-
dicating a significant deviation in SPLA (COOH/OH
ratio = 3.45) compared to linear PLA (COOH/OH ratio
close to 1). It clearly shows that a certain amount of the
lactic acid OH group had successfully reacted with the
COOH groups of pentetic acid (PA), thereby creating a
branched structure (Fig. 1a). 1H-NMR spectra are re-
ported in supportive information section.
Figure 1b presents FTIR-ATR spectra related to CS,
SPLA, and the CS-SPLA product.
According to the FTIR-ATR data reported (Wang
et al. 2014a, b), the more representative peaks for CS
are at 3313 cm−1 (–O–H stretching), 2873 cm−1 (–C–H),
1585 cm−1 (NH2 deformation), and 1045 cm
−1 (C–O–
C). SPLA shows a typical signal for PLA (Drumright
et al. 2000); these are at 2950 cm−1 (–CH– stretching);
1750 cm−1 (C=O stretching); 1452 cm−1 (CH3 bending);
1381 cm−1 and 1361 cm−1 (–CH– deformations and
asymmetric bending); 1267 cm−1 (C–O stretching );
1183 cm−1, 1128 cm−1, and 1084 cm−1 (C–O–C
stretching); and finally 1043 cm−1 (−C-CH3 bending).
The CS-SPLA spectra presents peaks at 1747 cm−1
(C=O stretching), 1648 cm−1—related to the amide
bond between CS amino groups and SPLA carboxylic
groups, and 1407 cm−1, representing the C–N stretching
that proves the occurrence of a coupling reaction.
The SEM micrographs (Fig. 2a–c) reveal that the
nanoparticles are spherical in shape but possess a greater
diameter than values recorded by DLS. As reported in
the published works (Pikal 2002; Abdelwahed et al.
2006a, b, c), the increase in dimension can be attributed
to the freeze-drying treatment performed without the use
of cryo or lyo protectors. The freezing and drying pro-
cesses generate stress that destabilizes the nanoparticle
suspension. During the freezing stage, a phase separa-
tion into ice and cryo-concentrated solution occurs. In
the suspension of nanoparticles, the cryo-concentrated
phase is composed of nanoparticles and other compo-
nents such as buffers and unloaded drugs (Abdelwahed
et al. 2006a, b, c). This high concentration of the partic-
ulate system may induce aggregation and in some cases
irreversible fusion of the nanoparticles. Moreover, ice
crystallization places a mechanical stress on the nano-
particles, leading to destabilization of the same
(Abdelwahed et al. 2006a, b, c).
However, as reported in the inner pane of Fig. 2b, the
distribution of diameters of the freeze-dried nanoparti-
cles after dissolution in preparation media and
Fig. 1 a Chemical structure of CS-SPLA (a, b, and c represent other possible points for the CS link). b FTIR-ATR spectra related to SPLA
(track A), CS (track B) and the CS-SPLA product obtained (track C)
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ultrasound treatment indicates that the aggregates are
not fully irreversible.
Nanoparticle characterization and TMZ loading
CS-SPLA complexes with DS forming nanoparticles
made of hydrophobic (SPLA) and hydrophilic (CS)
domain, in mildly acidic aqueous solution (pH 5.5).
The dimension, stability over time, and ζ-potential of
the CS-SPLA nanoparticles (loaded and unloaded) dis-
persed in said preparation media (pH 5.5) were investi-
gated by PCS and a ζ-potential analyzer. The results are
given in Table 1.
Table 1 presents results for nanoparticles loaded and
unloaded with TMZ.
PCS reveals the average diameter of unloaded nano-
particles lies in the range 150–180 nm in the preparation
media at room temperature.
Drug loading does not influence the ζ-potential,
which is around 30 mV. Despite the fact that the value
falls in the interval which is linked to incipient
instability/moderate stability, the prepared system
showed good stability in physiological conditions
(pH 7.4) and preparation media (pH 5.5) (Fig. 3).
Evaluating the stability of polymeric nanoparticles in
biological-like environments is critical to devising opti-
mal preparations and to developing notions on the fate
of nanoparticles after administration (Lazzari et al.
2012). Herein, the stability of the nanoparticles in the
preparation media (pH 5.5) and phosphate buffer
(pH 7.4) was researched in terms of change in average
diameter and ζ-potential over time.
The results obtained demonstrated the reasonable
stability of the nanoparticles under the given preparation
conditions (pH 5.5), showing an increase in size by 12%
after 2 weeks and 35% after 1 month. These results are
in agreement with those from the literature (You et al.
2013; Kumari et al. 2010) and confirm the stability of
CS-SPLA nanoparticles in solutions. However, shifting
the pH of the media from 5.5 to 7.4 led to remarkable
decreases in stability. At pH 7.4, the nanoparticles were
stable for up to 5 days, growing in dimension by around
14%. Afterward, aggregation and precipitation phenom-
ena began causing a rise in size by up to 150% com-
pared to that at the outset. Ultrasound treatment destroys
the aggregates formed, restoring dimensions to values
comparablewith those initially.However, after 1–2 days,
the aggregates reformed.
The values obtained fit with other data previously
published on polymeric nanoparticles, which were most-
ly based on polybutyl cyanoacrylate (PBCA) (Tian et al.
2011), poly (methyl malate) (Lanz-Landázuri et al.
2011), or PLGA (Zhang and Gao 2007) for TMZ encap-
sulation (Cho et al. 2008; Ling et al. 2012).
In the prepared system, CS-SPLA, at pH 5.5, and all
the functional groups—amino and carboxy—were in an
ionic state, allowing strong intra-electrostatic and inter-
electrostatic interactions between the chains. Moreover,
the ζ-potential value of +30 mV evidences a certain
stability that is due to repulsive forces between the
Fig. 2 SEM micrographs of a unloaded and b, c loaded CS-SPLA freeze-dried nanoparticles. Scale bars a 1 μm, b 10 μm, and c 5 μm
Table 1 Average dimension and ζ-potential of unloaded and loaded CS-SPLA nanoparticles and quantification of TMZ loading capacity
Average diameter (nm) ζ-pot. (mV) Encapsulation
efficiency (%)
Loading capacity mg TMZ/mg carrier
Unloaded Loaded Unloaded Loaded
165 ± 13 171 ± 15 +31 ± 2 +32 ± 3 81 ± 3 0.15 ± 0.01 0.26 ± 0.03
J Nanopart Res (2017) 19: 71 Page 7 of 16 71
nanoparticles. The amino groups became less protonat-
ed concurrently with increase in pH, which favored
aggregation. It has to be stated that an important role is
played by the concentration of the nanoparticles. The
results presented relate to the concentration of 1 mg/mL,
which could also substantiate the long-term stability
recorded. A remarkable increase in the viscosity of the
solution occurred when particle concentration equaled
10 mg/mL. Under the circumstances, not only did the
number of nanoparticles in the considered volume in-
crease but also mobility decreased, thereby favoring the
formation of aggregates even in the preparation media.
Table 1 and Fig. 3b resume the ζ-potential of bare
and loaded nanoparticles and the variation over time. No
substantial effect is observed over time in the prepara-
tion media (pH 5.5). Conversely, at pH 7.4, two phases
are identified. The first of these is where a sharp drop off
in ζ-potential occurs, followed by the other, where ζ-
potential values are stable over time. The rapid decrease
in ζ-potential is triggered by the rise in pH levels.
Actually, solid nanoparticles were dissolved in the me-
dia at pH 5.5, and afterward, the pHwas increased to 7.4
by adding phosphate buffer (pH 7.4).
The TMZ was loaded into the CS-SPLA nanoparti-
cles at a stage during preparation in order to obtain
higher EE values (Table 1).
The TMZ EE for CS-SPLA stands at approximately
80%, with a loading capacity of 0.15 in the preparation
media (pH 5.5). According to the reported data, the
amount of TMZ (mg) per mg of carrier is around 0.25;
this is comparable to—or in some cases higher than
similar polymeric systems reported in the literature
(Zhu and Liao 2015). Examples include TMZ loaded
into poly (D,L lactide-co-glycolide), where entrapment
efficiency ranged at 60–80% depending on the drug to
polymer ratio, and poly butyl cyanoacrylate (PBCA),
which has also been used as a vehicle for TMZ (Tian
et al. 2011), exhibiting an entrapment efficiency of up to
45%. Additionally, poly methyl-malate nanoparticles
have been prepared and loaded with TMZ in the past,
demonstrating merely 20–40% of entrapment efficiency
(Lanz-Landázuri et al. 2011).
Modifying the CS backbone by introducing a hydro-
phobic SPLA side chain directly influences the formation
process of the nanoparticles as well as accommodation of
the drug inside the structure (Juillerat-Jeanneret 2008).
In the encapsulation of various anticancer drugs (Tian
et al. 2011; Allard et al. 2009), it has been demonstrated
that the presence of hydrogen bonds between the drugs
and CS plays a key role in the rate of loading; in the
system under consideration, the OH and NH groups
constitute donors while the acceptors comprise O and N.
Fig. 3 Evaluation of nanoparticle stability in terms of a average
diameter and b ζ-potential variation over time in preparation
media (pH 5.5) and physiological solution (pH 7.4) at room
temperature. c Swelling percentages for CS-SPLA in different
media. Simulated gastric fluid (SGF, pH 2), preparation media
(PM, pH 5.5), and PBS (phosphate buffer, pH 7.4)
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According to data available on comparable systems
(Tian et al. 2011), in the case of CS-SPLA, the drug
tends to stay away from the CS backbone and situate
itself closer to any hydrophobic chains, causing a defi-
ciency in electrostatic interactions, which is in contrast
to behavior with hydrophobic types.
Conversely, in unmodified CS, the drugs are expect-
ed to position themselves closer to the CS backbone,
thereby causing more intense electrostatic interactions
(Tian et al. 2011). The high encapsulation efficiency
obtained by CS-SPLA could be ascribed to its greater
capacity for hydrophobic interaction in holding the drug
inside the system, as compared to electrostatic interac-
tion (Juillerat-Jeanneret 2008; Baker et al. 1999).
Swelling behavior in different media represents a
significant parameter for evaluation, as it directly influ-
ences release kinetics, in particular when the driving
force is diffusion. The swelling percentages for CS-
SPLA in media at various pH levels are illustrated in
Fig. 3. The presence of SPLA has a certain impact on the
swelling of CS-SPLA. The swelling behavior of unmod-
ified CS and CS grafted with linear PLA-based nanopar-
ticles was reported in a previous work by the authors (Di
Martino et al. 2015, Di Martino and Sedlarik 2014). The
results obtained demonstrated that the presence of SPLA
influenced at different intensities the displacement of
media molecules through the polymeric chains of the
system. As the pH rises from 2 in SGF to 7.4 in PBS,
there is a concurrent increase in the percentage of swell-
ing. This is explained by the pKa values for the NH2,
COOH, and SO3 groups involved in forming the
nanocomplexes. Raising the pH led to weakened electro-
static interactions between the NH3
+ and COO− groups,
due to deprotonation of NH3
+ to NH2. This permits faster
diffusion of the media inside the system (Pasparakis and
Bouropoulos 2006; Gasmi et al. 2015). The permeability
of the media can also be converted in response to an
alteration in environmental pH, which represents a desir-
able characteristic for a system with pH-sensitive con-
trolled release and controllable swelling ability.
TMZ release kinetics and stability studies
The act of releasing TMZ from the CS-SPLA nano-
particles was performed in two different media. In
order to evaluate the influence of pH, the authors
made particular use of SGF and PBS. The cumula-
tive release trend for the TMZ is shown in Fig. 4a,
b. Both media had been prepared in accordance with
European pharmacopeia standards.
As can be seen from the curves and k values obtained
by Eq. 6, increasing the pH of the media results in the
TMZ being released faster. In SGF, 50% of the loaded
drug was released in almost 24 h, while this took place
in PBS in less than 10 h. Moreover, as regards Cmax,
81% in PBS and 78% in SGF was reached in less than
2 days and after 3 days, respectively. As described in
both our previous and other studies (Di Martino et al.
2016; Di Martino et al. 2015; Srivastava et al. 2016;
Soares et al. 2016), such release is strictly bound with
the swelling index; in polyelectrolytes, swelling is di-
rectly influenced by the pH and ionic strength of the
surrounding environment. Furthermore, the presence of
hydrophobic side chains affects the swelling ability and
subsequently in the release of drugs, e.g., TMZ, which
are mildly soluble in water (5 mg/mL).
In comparison to past studies on the release of antican-
cer drugs from polymeric nanoparticles (Win and Feng
2005), observation was made of reduced release intensity
in the first 3 h after contact with the media, especially in
SGF, where only 5% of the loaded drug was released after
3 h, whereas in PBS this totaled around 20%.
This finding indicates that most of the loaded TMZ is
displaced in the inner section of the particles while there
is only a small amount on the surface, the latter being
immediately released after making contact with the me-
dia. The difference in intensity between PBS and SGF is
related to the degree of protonation of the ionic groups
along the CS backbone and CPLA side chains, which
are responsible for electrostatic interactions of the
intrachains and interchains. In acidic media, displace-
ment of the media molecules through the polymer
chains is delayed, or obstacles exist which reduce dis-
solution and cause subsequent diffusion of the TMZ
molecules (Di Martino and Sedlarik 2014).
Delaying TMZ hydrolysis in MTIC (active metabo-
lite) and AIC (inactive) is desirable, in particular under
physiological conditions where pH >7 represents a chal-
lenge. The hydrolysis mechanism for TMZ has previ-
ously been described and thoroughly investigated
through different methodologies (Denny et al. 1994;
Wheelhouse and Stevens 1993; Lopes et al. 2013).
Figure 5 shows a simplified illustration of TMZ
hydrolysis at pH >7.
TMZ ring-opening commences by adding a water
molecule to carbonyl moiety. Afterward, intermediate
(MTIC) is generated, resulting from elimination of CO2.
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MTIC decomposes quickly and releases methylated
species (methyldiazonium ion) and 4-amino-5-
imidazole-carboxamide (AIC); the latter is not active
(Fig. 5). The mechanism of degradation is highly pH
sensitive, the rate of TMZ increasing according to the
pH of the media. The TMZ t1/2 in phosphate buffer of
pH 7.4 stands at less than 2 h, while at pH < 4, it is up to
24 h (Kim et al. 2001). Moreover, other subproducts
(Fig. 6) from MTIC degradation can be generated
(Chowdhury et al. 1999).
In Fig. 6, the MS spectra of free TMZ over time in
aqueous media at pH 7.4 is displayed.
Comparing the MS spectra in Fig. 6a–c, it is
revealed that the degradation of TMZ in MTIC and
AIC and other subproducts. At time zero (see
Fig. 6a), in accordance with published works
(Darkes et al. 2002; Di Martino et al. 2016), TMZ
exhibits an ion at m/z 195 [M + H]+ and K adduct at
217, respectively. After 3 h of TMZ dissolution in
the media, new peaks appear at m/z 169 (ascribable
to [MTIC + H]+) and m/z 127, related to [AIC +
H]+. However, TMZ still remains in the media. The
presence of AIC is due to the low stability of MTIC,
which tends to degrade in AIC over the period of
minutes. After 24 h following dissolution (Fig. 6c),
all the TMZ is hydrolyzed, and the main compound
present in the media is highly stable AIC. The other
peaks in Fig. 6c, in particular 4, 5, and 6, could
relate to products resulting from the MTIC degrada-
tion of MTIC in AIC, as reported in previous studies
(Jakobsen et al. 2001; Fiore et al. 1985).
Figure 7 presents the MS spectra for the TMZ re-
leased from the CS-SPLA nanoparticles after 3 and 24 h.
A clear difference is visible between the spectra in
Figs. 6 and 7. The latter reveals that the TMZ released
after 6 h is still not hydrolyzed, indicating that the
hydrolysis phenomena is considerably delayed when
the drug is loaded in CS-SPLA nanoparticles. After
24 h (Fig. 7c), the peaks at m/z 195 (related to [TMZ +
H]+) remain intense. However, the peaks referencing
metabolites atm/z 169 [MTIC +H]+ andm/z 127 [AIC +
H]+ are present.
These findings are also supported by UVanalysis, as
reported in Fig. 8.
Fig. 4 Release trend for TMZ from CS-SPLA nanoparticles in SGF (pH 2) and PBS (pH 7.4) at 37 °C. a Overall release; R2 > 0.99,
k = 0.009 in SGF, and k = 0.015 in PBS. b Amount of drug released in the first 3 h
Fig. 5 Schematic representation of TMZ hydrolysis
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Figure 8a displays the UV spectra for TMZ in pH 7.4
aqueous solution, collected at different times. Initially,
the fresh solution presents three absorption bands at 212,
252, and 327 nm typical for TMZ, as reported in the
literature (Lopes et al. 2013).
As can be seen, the intensity of the three bands
decreases after 6 and 24 h, indicating hydrolysis of the
TMZ, following the reaction illustrated in Fig. 5. Con-
versely, TMZ is preserved when loaded in the CS-SPLA
nanoparticles, as after 6 h, no changes are observed in
the intensity of band at the monitored wavelengths.
Only after 24 h is a drop in intensity visible, in particular
at 327 and 252 nm, indicating that hydrolysis has taken
place. However, considering theMS results that confirm
the structure of the TMZ and limited presence of hydro-
lysis products such as MTIC, AIC, or another subprod-
uct, the diminished intensity of the band might relate to
hydrolysis of TMZ release that occurred previously in
the media, beyond the protection of the nanoparticles.
The MS and UV results reported herein demonstrate
the delay of TMZ hydrolysis when loaded in CS-SPLA
nanoparticles. Besides, several studies (Ananta et al.
Fig. 6 MS spectra for TMZ in aqueous solution at pH 7.4 at a time 0, b after 3 h, and c after 24 h. The reported chemical structures are 1
TMZ; 2 MTIC; 3 AIC; while 4, 5, 6 represent side products from MTIC degradation
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2016; Mehare et al. 2015; Nygren and Eksborg 2012;
Xu et al. 2016) dealing with encapsulation of TMZ in
carrier to improve the therapeutical performances not so
much is reported regarding the use of nano or micro
carrier to reduce the hydrolysis of TMZ in its
metabolites and prolong the half -life. The presented
MS and UV results prove that by loading TMZ in CS-
SPLA-based nanoparticles, it is possible to protect the
prodrug from the external environment and delay the
hydrolysis up to 24 h and preserving the therapeutic
efficacy as reported in Fig. 10.
Cytotoxicity and cell morphology evaluation
NIH/3T3 and MEF cell lines have been widely used for
cytotoxicity testing for decades; cytotoxicity is evaluat-
ed as a decrease in cell viability (determined by anMTT
assay) compared to the reference.
The cytotoxicity studies (Fig. 9) showed the follow-
ing: (i) TMZ exhibited no cytotoxicity when applied as
the free drug, due to its hydrolysis into inactive products
that occurs in less than 30 min after contact with phys-
iological media at pH > 7; (ii) the viability of the cells
was unaffected by the bare nanoparticles made of CS-
SPLA in the range of concentration 0.5–5 μg mL−1 in
the cultivation medium (viability above 80%).
Fig. 7 MS spectra for a TMZ as control and TMZ released from
nanoparticles after b 6 and c 24 h in aqueous solution of pH 7.4
Fig. 8 UV spectra for a free TMZ, control solution, and b TMZ
released from nanoparticles. The pH level of the control solution
and release media equals 7.4
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As reported in Fig. 9, the viability of the NIT/3T3 and
MEF cells dropped when TMZ was loaded into the CS-
SPLA nanoparticles. Furthermore, cell viability tended
to decrease over time, reaching values below 5% after
72 h. This clearly demonstrates that the prepared poly-
meric nanoparticles protect TMZ from hydrolysis. The
significant impact of the nanoparticles in preserving
TMZ from the hydrolysis is evident. Free TMZ quickly
hydrolyse in the inactive metabolites in the time elapses
between the sample preparation and the contact with the
media, resulting incative. At the same time, when TMZ
is loaded in CS-SPLA carrier, the hydrolysis does not
take place preserving and prolonging the cytotoxic ef-
fect over time.
The capability of the carrier to preserve the struc-
ture and activity is additionally revealed by the
micrographs (Fig. 10). Comparing the number of
nuclei for pure CS-SPLA (Fig. 10a) with the carrier
containing the drugs clearly shows that quantity of
cells significantly diminishes (Fig. 10b, c). As the
actin filamets are also counterstained, remarkable
differences in cell growth, and spread are also obvi-
ous. Based on cell quantification as well as micro-
graphs, it can be concluded that CS-SPLA-based
nanoparticles demonstrably improve TMZ stability
and preserving efficacy in terms of cytotoxicity is
applicable in order to protect the structure of TMZ
from hydrolysis and boost its cytotoxicity.
Fig. 9 NIH/3T3 and MEF viability dependences on unloaded TMZ and bare CS-SPLA nanoparticles (a–c), and CS-SPLA nanoparticles
loaded with TMZ, over time
Fig. 10 Inverted fluorescent microscopy observation of NIH/3T3 cells after a CS-SPLA, b CS-SPLA + TMZ (24 h), and c CS-SPLA
+TMZ (48 h)
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Conclusions
The authors have described a novel kind of amphi-
philic copolymer (CS-SPLA), which was obtained
by grafting a natural polysaccharide CS with
carboxy-enriched polylactic acid (SPLA) to load
and improve the stability of the anticancer prodrug
TMZ in physiological conditions. The resultant
product maintains the properties of the main constit-
uent, chitosan, in particular the cationic characteris-
tics and the solubility. The average dimension and ζ-
potential of the prepared carrier felt in the range
150–180 nm and 28–33 mV, respectively. TMZ
was encapsulated with high efficiency, up to 80%,
and no significant changes in the dimension and ζ-
potential were detected after encapsulation. More-
over, the prepared system showed good stability in
preparation media (pH 5.5) and physiological solu-
tion (pH 7.4) up to 1 month. MS and UV analysis
clearly demonstrated the role of CS-SPLA in
protecting and preventing hydrolysis of TMZ in
MTIC, and subsequently in AIC in physiological
conditions. It represents a great advantage as the
main drawback of TMZ is the fast degradation in
physiological conditions which causes a reduction in
its therapeutic efficacy and an increase in the ad-
ministration frequency. Release kinetics studies re-
vealed the capability of regulating the release rate
according to the pH of the external environment.
The improvement in TMZ stability, but also the
subsistence of its cytotoxicity effect when loaded
into the CS-SPLA nanoparticles, was demonstrated
by in vitro tests on NIH/3T3 and MEF cell cultures,
where TMZ cytotoxicity lasted up to 72 h from the
moment of contact. It gives a further confirmation of
the ability of CS-SPLA nanoparticles to improve the
hydrolytic stability of TMZ, which can enhance
therapeutic efficiency of the cytostatic drug.
Acknowledgements This work was funded by the Czech Sci-
ence Foundation (grant no. 15-08287Y), Ministry of Education,
Youth and Sports of the Czech Republic (grants nos. LO1504 and
CZ.1.05/2.1.00/19.0409), and Internal Grant Agency of the Tomas
Bata University in Zlin (grant no. IGA/CPS/2016/004)
Compliance with ethical standards The research carried out
within this work did not involve human participants and/or
animals.
Conflict of interest The authors declare that they have no con-
flict of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestrict-
ed use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if
changes were made.
References
Abdelwahed W, Degobert G, Stainmesse S, Fessi H (2006a)
Freeze-drying of nanoparticles: formulation, process and
storage considerations. Adv Drug Deliv Rev 58(15):1688–
1713
Abdelwahed W, Degobert G, Fessi H (2006b) A pilot study of
freeze drying of poly (epsilon-caprolactone) nanocapsules
stabilized by poly (vinyl alcohol): formulation and process
optimization. Int J 309(1):178–188
Abdelwahed W, Degobert G, Fessi H (2006c) Investigation of
nanocapsules stabilization by amorphous excipients during
freeze-drying and storage. Eur J Pharm and Biopharm 63(2):
87–94
Agarwala SS, Kirkwood JM (2000a) Promising new drugs and
combinations. Oncologist 5:144–151
Agarwala SS, Kirkwood JM (2000b) Temozolomide, a novel
alkylating agent with activity in the central nervous system,
may improve the treatment of advanced metastatic melano-
ma. Oncologist 5(2):144–151
Allard E, Passirani C, Benoit JP (2009) Convection-enhanced
delivery of nanocarriers for the treatment of brain tumours.
Biomaterials 30(12):2302–2318
Ananta SJ, Paulmurugan R, Massoud TF (2016) Temozolomide-
loaded PLGA nanoparticles to treat glioblastoma cells: a
biophysical and cell culture evaluation. Neurol Res 38(1):
51–59
Appel EA, Rowland MJ, Loh XJ, Heywood RM, Watts C,
Scherman OA (2012) Enhanced stability and activity of
temozolomide in primary glioblastoma multiforme cells with
cucurbit [n] uril. Chem Comm 48(79):9843–9845
Bajpai AK, Anjali G (2003) Water sorption behavior of highly
swelling (carboxy methylcellulose-gpolyacrylamide)
hydrogels and release of potassium nitrate as agrochemical.
Carbohydr Polym 53(3):271-279
Bajpai J, Maan GK, Bajpai AK (2012) Preparation, characteriza-
tion and water uptake behavior of polysaccharide based
nanoparticles: swelling behaviour of nanoparticles. Prog
Nanotech Nanomater 1:9–17
Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K,
Sartorius SE, Donehower RC (1999) Absorption, metabo-
lism, and excretion of 14C-temozolomide following oral
administration to patients with advanced cancer. Clin
Cancer Res 5(2):309–317
Bowman K, Leong KW (2006) Chitosan nanoparticles for oral
drug and gene delivery. Int J Nanomedicine 1(2):117-128
Cho K, Wang XU, Nie S, Shin DM (2008) Therapeutic nanopar-
ticles for drug delivery in cancer. Clin Cancer Res 14(5):
1310–1316
71 Page 14 of 16 J Nanopart Res (2017) 19: 71
Chowdhury SK, Laudicina D, Blumenkrantz N, Wirth M, Alton
KB (1999) An LC/MS/MS method for the quantitation of
MTIC (5-(3-N-methyl tr iazen-1-yl)- imidazole-4-
carboxamide), a bioconversion product of temozolomide, in
rat and dog plasma. J Pharmaceut Biomed 19(5):659–668
Darkes MJ, Plosker GL, Jarvis B (2002) Temozolomide. Am J
Cancer 1(1):55–80
Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA
(1994) NMR and molecular modeling investigation of the
mechanism of activation of the antitumor drug temozolomide
and its interaction with DNA. Biochem 33(31):9045-9051
Di Martino A, Sedlarik V (2014) Amphiphilic chitosan-grafted-
functionalized polylactic acid based nanoparticles as a deliv-
ery system for doxorubicin and temozolomide co-therapy. Int
J Pharm 474(1):134–145
Di Martino A, Kucharczyk P, Zednik J, Sedlarik V (2015)
Chitosan grafted low molecular weight polylactic acid for
protein encapsulation and burst effect reduction. Int J Pharm
496(2):912–921
Di Martino A, Pavelkova A, Maciulyte S, Budriene S, Sedlarik V
(2016) Polysaccharide-based nanocomplexes for co-
encapsulation and controlled release of 5-fluorouracil and
temozolomide. Eur J Pharm Sci 92:276–286
Dresemann G (2010) Temozolomide in malignant glioma. Onco
Targets Ther 3:139–146
Drumright RE, Gruber PR, Henton DE (2000) Polylactic acid
technology. Advanced Mmaterials 12(23):1841–1846
El-Sharief AMS, Al-Amri AM, Al-Raqa SY (2006) Halogenated,
alkylated and new types of imidazolidine, pyrrolidine,
imidazotriazine and thienoimidazole derivatives with biolog-
ical and antitumor activities. J Sulfur Chem 27(03):245–263
Fahr A, Liu X (2007) Drug delivery strategies for poorly water-
soluble drugs. Expert Opin Drug Del 4(4):403–416
Fiore D, Jackson AJ, Didolkar MS, Dandu VR (1985)
Simultaneous determination of dacarbazine, its photolytic
degradation product, 2-azahypoxanthine, and the metabolite
5-aminoimidazole-4-carboxamide in plasma and urine by
high-pressure liquid chromatography. Antimicrob Agents
Chemother 27(6):977–979
Gasmi H et al (2015) Does PLGA microparticle swelling control
drug release? New insight based on single particle swelling
studies. J Control Release 213:120–127
Ge W, Li D, Chen M, Wang X, Liu S, Sun R (2015)
Characterization and antioxidant activity of β-carotene load-
ed chitosan-graft-poly (lactide) nanomicelles. Carbohydr
Polym 117:169–176
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N,
Weller M, Bromberg JE (2005) MGMT gene silencing and
benefit from temozolomide in glioblastoma. N Engl J Med
352(10):997–1003
Huang S, Wan Y, Wang Z, Wu J (2013) Folate-conjugated chito-
san–polylactide nanoparticles for enhanced intracellular up-
take of anticancer drug. JNR 15(12):1–15
Jain DS, Athawale RB, Bajaj AN, Shrikhande SS, Goel PN,
NikamY, Gude RP (2014) Unraveling the cytotoxic potential
of Temozolomide loaded into PLGA nanoparticles. DARU
22(1):18
Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE (2001). 5'-
AMP-activated protein kinase phosphorylates IRS-1 on Ser-
789 in mouse C2C12 myotubes in response to 5-
aminoimidazole-4-carboxamide riboside. J Biol Chem 14,
276, 50, 46912–46916
Jeyarama AS, Paulmurugan R, Tarik FM (2016) Temozolomide-
loaded PLGA nanoparticles to treat glioblastoma cells: a
biophysical and cell culture evaluation. Neurol Res 38(1):
51-59
Juillerat-Jeanneret L (2008) The targeted delivery of cancer drugs
across the blood–brain barrier: chemical modifications of
drugs or drug-nanoparticles? Drug Discov Today 13(23):
1099–1106
Kim H, Likhari P, Parker D, Statkevich P, Marco A, Lin CC,
Nomeir AA (2001) High-performance liquid chromatograph-
ic analysis and stability of anti-tumor agent temozolomide in
human plasma. J Pharm Biomed Anal 24(3):461–468
Koo YEL, Reddy GR, Bhojani M, Schneider R, Philbert MA,
Rehemtulla A, Kopelman R (2006) Brain cancer diagnosis
and therapy with nanoplatforms. Adv Drug Deliver Rev
58(14):1556–1577
Kucharczyk P, Zednik J, Sedlarik V (2016). Star-shaped carboxyl
group functionalized poly(lactic) prepared through polycon-
densation reaction. Submitted fopr publication to
Macromolecular chemistry and Physics 2016- Under revision
Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric
nanoparticles based drug delivery systems. Colloids Surf B
Biointerfaces 75(1):1–18
Lagona J, Mukhopadhyay P, Chakrabarti S, Isaacs L (2005) The
cucurbit [n] uril family. AngewChem Int Ed 44(31):4844–
4870
Lanz-Landázuri A, García-Alvarez M, Portilla-Arias J, Martínez
de Ilarduya A, Patil R, Holler E, Muñoz-Guerra S (2011)
Poly (methyl malate) nanoparticles: formation, degradation,
and encapsulation of anticancer drugs. Macromol Biosci
11(10):1370–1377
Lazzari S, Moscatelli D, Codari F, Salmona M, Morbidelli M,
Diomede L (2012) Colloidal stability of polymeric nanopar-
ticles in biological fluids. JNR 14(6):1–10
Ling Y, Wei K, Zou F, Zhong S (2012) Temozolomide loaded
PLGA-based superparamagnetic nanoparticles for magnetic
resonance imaging and treatment of malignant glioma. Int J
Pharm 430(1):266–275
Lopes IC, de Oliveira SCB, Oliveira-Brett AM (2013)
Temozolomide chemical degradation to 5-aminoimidazole-
4-carboxamide–electrochemical study. J Electroanal Chem
704:183–189
Lu W, Sun Q, Wan J, She Z, Jiang XG (2006) Cationic albumin–
conjugated pegylated nanoparticles allow gene delivery into
brain tumors via intravenous administration. Cancer Res
66(24):11878–11887
Matosiuk D, Fidecka S, Antkiewicz-Michaluk L, Lipkowski J,
Dybala I, Koziol AE (2002) Synthesis and pharmacological
activity of new carbonyl derivatives of 1-aryl-2-
iminoimidazolidine: part 2. Synthesis and pharmacological
activity of 1, 6-diaryl-5, 7 (1H) dioxo-2, 3-dihydroimidazo
[1, 2-a][1, 3, 5] triazines. Eur J Med Chem 37(9):761–772
McCarron PA, Hall M (2004) Pharmaceutical nanotechnology.
Encycl Nanosci Nanotechnol 8:469-487
Meer L, Janzer RC, Kleihues P, Kolar GF (1986) In vivo metab-
olism and reaction with DNA of the cytostatic agent, 5-(3, 3-
dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC).
Biochem Pharmacol 35(19):3243–3247
J Nanopart Res (2017) 19: 71 Page 15 of 16 71
Mehare G, Sengodan T, Tamizharasi S, Sivakumar T, Sawarkar S,
Piyush CP (2015) Formulation and characterization of pla
nanoparticles of temozolomide. EJPMR 2(5):1089-1100
Nygren H, Eksborg S (2012) Stability of temozolomide in
solutions aimed for oral treatment prepared from a com-
mercially available powder for infusion. Pharm Methods
3:1,1–1,3
Pasparakis G, Bouropoulos N (2006) Swelling studies and in vitro
release of verapamil from calcium alginate and calcium algi-
nate–chitosan beads. Int J Pharm 323(1):34–42
Pikal MJ (2002) Freeze drying. In: Swarbrick J (ed) Encyclopedia
of pharmaceutical technology, vol 2. Marcel Dekker, New
York, pp 1299–1326
Sinha VR, Kumria R (2001) Polysaccharides in colon-specific
drug delivery. Int J Pharm 224(1):19–38
Soares PI, Sousa AI, Silva JC, Ferreira IM, Novo CM, Borges JP
(2016) Chitosan-based nanoparticles as drug delivery sys-
tems for doxorubicin: optimization and modelling.
Carbohydr Polym 147:304–312
Srivastava G, Walke S, Dhavale D, Gade W, Doshi J, Kumar R,
Doshi P (2016) Tartrate/tripolyphosphate as co-crosslinker
for water soluble chitosan used in protein antigens encapsu-
lation. Int J Biol Macromolec 91:381–393
Tian XH, Lin XN, Wei F, Feng W, Huang ZC, Wang P, Diao Y
(2011) Enhanced brain targeting of temozolomide in
polysorbate-80 coated polybutylcyanoacrylate nanoparticles.
Int J Nanomedicine 6:445–452
Tyndall EM, Draffan AG, Frey B, Pool B, Halim R, Jahangiri S,
Thomas J (2015) Prodrugs of imidazotriazine and
pyrrolotriazine C-nucleosides can increase anti-HCVactivity
and enhance nucleotide triphosphate concentrations in vitro.
Bioorg Med Chem Lett 25(4):869–873
Wang H, Xu Y, Zhou X (2014a) Docetaxel-loaded chitosan mi-
crospheres as a lung targeted drug delivery system: in vitro
and in vivo evaluation. Int J Mol Sci 15(3):3519–3532
Wang Q, Liu P, Liu P, Gong T, Li S, Duan Y, Zhang Z (2014b)
Preparation, blood coagulation and cell compatibility evalu-
ation of chitosan-graft-polylactide copolymers. Biomed
Mater 9(1):015007
Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J
Med 359(5):492–507
Wheelhouse RT, Stevens MF (1993) Decomposition of the
antitumour drug temozolomide in deuteriated phosphate
buffer: methyl group transfer is accompanied by deuterium
exchange. J Chem Soc Chem Comm 15:1177–1178
Win KY, Feng SS (2005) Effects of particle size and surface
coating on cellular uptake of polymeric nanoparticles for
oral delivery of anticancer drugs. Biomaterials 26(15):
2713–2722
Xu Y, Shen M, Li Y, Sun Y, Teng Y, Wang Y, Duan Y (2015) The
synergic antitumor effects of paclitaxel and temozolomide
co-loaded in mPEG-PLGA nanoparticles on glioblastoma
cells. Oncotarget 7:15
Xu Y, Shen M, Sun Y, Gao P, Duan Y (2016) Nano composite
thermo-sensitive gel for paclitaxel and temozolomide co-
delivery to glioblastoma cells. J Nanosci Nanotechnol
16(12):12288-12298
You J, Li W, Yu C, Zhao C, Jin L, Zhou Y, Wang O (2013)
Amphiphilically modified chitosan cationic nanoparticles
for drug delivery. JNR 15(12):1–10
Zhang H, Gao S (2007) Temozolomide/PLGA microparticles and
antitumor activity against glioma C6 cancer cells in vitro. Int
J Pharm 329(1):122–128
Zhu Y, Liao L (2015) Applications of nanoparticles for anticancer
drug delivery: a review. JNN 15(7):4753–4773
71 Page 16 of 16 J Nanopart Res (2017) 19: 71
